Cancer vaccines

Oncologist

Volumn 7, Issue SUPPL. 3, 2002, Pages 20-33

  Espinoza Delgado, Igor ^a  

^a NATIONAL INSTITUTE ON AGING   (United States)

Author keywords

Cancer; Dendritic cells; Immunotherapy; Vaccines

Indexed keywords

ALPHA FETOPROTEIN; ALPHA2A INTERFERON; BCR ABL PROTEIN; CANCER VACCINE; GANGLIOSIDE GM2; GLYCOPROTEIN GP 100; IMMUNOGLOBULIN IDIOTYPE; INTERLEUKIN 10; MACROGOL; MONOPHENOL MONOOXYGENASE; MUCIN 1; T LYMPHOCYTE RECEPTOR; TRANSFORMING GROWTH FACTOR BETA; TUMOR ANTIGEN; VASCULOTROPIN;

ANTIGEN PRESENTING CELL; CANCER IMMUNOTHERAPY; CANCER PREVENTION; CLINICAL TRIAL; COLON CANCER; CONFERENCE PAPER; DENDRITIC CELL; GLIOBLASTOMA; HUMAN; IMMUNE RESPONSE; IMMUNOLOGICAL TOLERANCE; IMMUNOSURVEILLANCE; LYMPHOMA; MELANOMA; MULTIPLE MYELOMA; PRIORITY JOURNAL; PROSTATE CANCER; T LYMPHOCYTE; TUMOR CELL; VACCINATION; ACTIVE IMMUNIZATION; NEOPLASM; REVIEW;

CANCER VACCINES; CLINICAL TRIALS; HUMANS; IMMUNOTHERAPY, ACTIVE; NEOPLASMS;

EID: 0036054464     PISSN: 10837159     EISSN: None     Source Type: Journal    
DOI: 10.1634/theoncologist.7-suppl_3-20     Document Type: Conference Paper

References (131)

1. Spontaneous regression of cancer
2. Spontaneous regression of metastatic renal cancer. Case report and literature review
3. Analysis of the association of peptides of optimal length to class I molecules on the surface of cells
4. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma
5. Generation of human cytotoxic T cells specific for human carcinoembryonic antigen epitopes from patients immunized with recombinant vaccinia-CEA vaccine
6. Tumor antigens recognized by T cells
7. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: Half of patients respond to a four-dose treatment program
8. Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma: Safety and efficacy of re-treatment
9. Rituximab (anti-CD20 monoclonal antibody) as single first-line therapy for patients with follicular lymphoma with a low tumor burden: Clinical and molecular evaluation
10. Phase II multicenter study of human CD52 antibody in previously treated chronic lymphocytic leukemia
11. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease
12. Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer
13. Durability of complete responses in patients with metastatic cancer treated with high-dose interleukin-2: Identification of the antigens mediating response
14. Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy
15. High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: Analysis of 270 patients treated between 1985 and 1993
16. The biochemistry and cell biology of antigen processing and presentation
17. Signals arising from antigen-presenting cells
18. Identification of an alternative CTLA-4 ligand costimulatory for T cell activation
19. Pivotal role of the B7:CD28 pathway in transplantation tolerance and tumor immunity
20. Costimulation of T lymphocytes: The role of CD28, CTLA-4, and B7/BB1 in interleukin-2 production and immunotherapy
21. In vitro induction of T cell anergy by blocking B7 and early T cell costimulatory molecule ETC1/B7-2
22. A cell culture model for T lymphocyte clonal anergy
23. The Yin and Yang of T cell costimulation
24. Induction of antigen-specific T cell anergy: An early event in the course of tumor progression
25. Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells
26. Aberrant antigen presentation by macrophages from tumor-bearing mice is involved in the down-regulation of their T cell responses
27. The onset and extent of genomic instability in sporadic colorectal tumor progression
28. Genetic instability and tumor cell variation: Implications for immunotherapy
29. A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia-telangiectasia
30. Tolerance, danger, and the extended family
31. Danger versus tolerance: Paradigms for future studies of tumor-specific cytotoxic T lymphocytes
32. Neonatal tolerance revisited: Turning on newborn T cells with dendritic cells
33. Coley's toxins, tumor necrosis factor and cancer research: A historical perspective
34. The treatment of malignant tumors by repeated inoculations of erysipelas: With a report of ten original cases
35. Causing a commotion in the blood: Immunotherapy progresses from bacteria to bacterial DNA
36. Antitumor activity of deoxyribonucleic acid fraction from Mycobacterium bovis BCG. I. Isolation, physicochemical characterization, and antitumor activity
37. CpG motifs in bacterial DNA trigger direct B-cell activation
38. Macrophages ingest and are activated by bacterial DNA
39. Bacterial CpG-DNA activates dendritic cells in vivo: T helper cell-independent cytotoxic T cell responses to soluble proteins
40. Oligodeoxy-nucleotides containing CpG motifs can induce rejection of a neuroblastoma in mice
41. Lipid-DNA complexes induce potent activation of innate immune responses and antitumor activity when administered intravenously
42. Immunization with a peptide epitope (p369-377) from HER-2/neu leads to peptide-specific cytotoxic T lymphocytes that fail to recognize HER2/neu+ tumors
43. Emerging concepts in cancer vaccine development
44. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma
45. Identification of HLA-A*0201-restricted CTL epitopes encoded by the tumor-specific MAGE-2 gene product
46. From defined human tumor antigens to effective immunization?
47. Identification of a gene encoding a melanoma tumor antigen recognized by HLA-A31-restricted tumor-infiltrating lymphocytes
48. Identification of TRP-2 as a human tumor antigen recognized by cytotoxic T lymphocytes
49. The tyrosinase gene codes for an antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas
50. Identification of a human melanoma antigen recognized by tumor-infiltrating lymphocytes associated with in vivo tumor rejection
51. Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor
52. A processed pseudogene codes for a new antigen recognized by a CD8(+) T cell clone on melanoma
53. A p16INK4a-insensitive CDK4 mutant targeted by cytolytic T lymphocytes in a human melanoma
54. Progress in human tumour immunology and immunotherapy
55. Enhancement of cellular immunity in melanoma patients immunized with a peptide from MART-1/Melan A
56. Immunization against epitopes in the human melanoma antigen gp100 following patient immunization with synthetic peptides
57. Evaluation of CD8(+) T-cell frequencies by the Elispot assay in healthy individuals and in patients with metastatic melanoma immunized with tyrosinase peptide
58. High frequencies of circulating melanoma-reactive CD8+ T cells in patients with advanced melanoma
59. An expanded peripheral T cell population to a cytotoxic T lymphocyte (CTL)-defined, melanocyte-specific antigen in metastatic melanoma patients impacts on generation of peptide specific CTLs but does not overcome tumor escape from immune surveillance in metastatic lesions
60. Improved induction of melanoma-reactive CTL with peptides from the melanoma antigen gp100 modified at HLA-A*0201-binding residues
61. Recombinant virus vaccination against "self" antigens using anchor-fixed immunogens
62. Improved survival in stage III melanoma patients with GM2 antibodies: A randomized trial of adjuvant vaccination with GM2 ganglioside
63. High-dose interferon alpha-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: Results of intergroup trial E1694/S9512/C509801
64. High-dose interferon alpha-2b does not diminish antibody response to GM2 vaccination in patients with resected melanoma: Results of the Multicenter Eastern Cooperative Oncology Group Phase II Trial E2696
65. Signaling defects in T lymphocytes of patients with malignancy
66. Alteration of signal transduction in T cells from cancer patients
67. T-cell-directed cancer vaccines: Mechanisms of immune escape and immune tolerance
68. Mechanisms of immune evasion by renal cell carcinoma: Tumor-induced T-lymphocyte apoptosis and NFkappaB suppression
69. Dendritic cells and the control of immunity
70. Dendritic cells: On the move from bench to bedside
71. Peptide-pulsed dendritic cells induce antigen-specific CTL-mediated protective tumor immunity
72. Bone marrow-derived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic antitumour immunity
73. Murine dendritic cells pulsed in vitro with tumor antigen induce tumor resistance in vivo
74. Enhancement of cytolytic T lymphocyte precursor frequency in melanoma patients following immunization with the MAGE-1 peptide loaded antigen presenting cell-based vaccine
75. Induction of antigen-specific cytolytic T cells in situ in human melanoma by immunization with synthetic peptide-pulsed autologous antigen presenting cells
76. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells
77. Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells
78. Idiotype-pulsed dendritic cell vaccination for B-cell lymphoma: Clinical and immunological responses in 26 patients
79. Idiotype vaccination using dendritic cells after autologous peripheral blood stem cell transplantation for multiple myeloma - A feasibility study
80. Vaccination of multiple myeloma patients with idiotype-pulsed dendritic cells: Immunological and clinical aspects
81. A phase I study of active immunotherapy with carcinoembryonic antigen peptide (CAP-1)-pulsed, autologous human cultured dendritic cells in patients with metastatic malignancies expressing carcinoembryonic antigen
82. Phase I clinical trial: T-cell therapy for prostate cancer using autologous dendritic cells pulsed with HLA-A0201-specific peptides from prostate-specific membrane antigen
83. Evaluation of phase I/II clinical trials in prostate cancer with dendritic cells and PSMA peptides
84. Follow-up evaluation of a phase II prostate cancer vaccine trial
85. Immunotherapy of hormone-refractory prostate cancer with antigen-loaded dendritic cells
86. Priming tissue-specific cellular immunity in a phase I trial of autologous dendritic cells for prostate cancer
87. Vaccination of malignant glioma patients with peptide-pulsed dendritic cells elicits systemic cytotoxicity and intracranial T-cell infiltration
88. Controlled trial of active immunotherapy in management of stage IIB malignant melanoma
89. Serological responses of melanoma patients to vaccines derived from allogeneic cultured melanoma cells
90. Serological response of melanoma patients receiving melanoma cell vaccines. I. Autologous cultured melanoma cells
91. Active specific immunotherapy for stage II and stage III human colon cancer: A randomised trial
92. Adjuvant active specific immunotherapy for stage II and III colon cancer with an autologous tumor cell vaccine: Eastern Cooperative Oncology Group Study E5283
93. Induction of melanoma antigen-specific cytotoxic T lymphocytes in vitro by stimulation with B7-expressing human melanoma cell lines
94. Interleukin-2 production by tumor cells bypasses T helper function in the generation of an antitumor response
95. Treatment of established renal cancer by tumor cells engineered to secrete interleukin-4
96. Tumor rejection after direct costimulation of CD8+ T cells by B7-transfected melanoma cells
97. Immunotherapy of malignancy by in vivo gene transfer into tumors
98. Vaccination with irradiated tumor cells engineered to secrete murine granulocytemacrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity
99. A phase I trial of B7-transfected or parental lethally irradiated allogeneic melanoma cell lines to induce cell-mediated immunity against tumor-associated antigen presented by HLA-A2 or HLA-A1 in patients with stage IV melanoma. NCI protocol T93-0161. BRMP protocol 9401
100. Bioactivity of autologous irradiated renal cell carcinoma vaccines generated by ex vivo granulocyte-macrophage colony-stimulating factor gene transfer
101. Novel allogeneic granulocyte-macrophage colony-stimulating factor-secreting tumor vaccine for pancreatic cancer: A phase I trial of safety and immune activation
102. Semiallogeneic cancer vaccines formulated with granulocyte-macrophage colony-stimulating factor for patients with metastatic gastrointestinal adenocarcinomas: A pilot phase I study
103. Murine interleukin-4 displays potent anti-tumor activity in vivo
104. Human tumor antigens recognized by T lymphocytes
105. Identification of the genes encoding cancer antigens: Implications for cancer immunotherapy
106. Identification of HLA-A2-restricted T-cell epitopes derived from the MUC1 tumor antigen for broadly applicable vaccine therapies
107. Protective antitumor immunity induced by immunization with completely allogeneic tumor cells
108. Enhanced tumor protection by granulocyte-macrophage colony-stimulating factor expression at the site of an allogeneic vaccine
109. Active immunization of metastatic melanoma patients with interleukin-2-transduced allogeneic melanoma cells: Evaluation of efficacy and tolerability
110. Induction of antitumor activity by immunization with fusions of dendritic and carcinoma cells
111. Activation of antitumor cytotoxic T lymphocytes by fusions of human dendritic cells and breast carcinoma cells
112. Reversal of tolerance to human MUC1 antigen in MUC1 transgenic mice immunized with fusions of dendritic and carcinoma cells
113. Regression of human metastatic renal cell carcinoma after vaccination with tumor cell-dendritic cell hybrids
114. Tumor-dendritic cell fusion technology and immunotherapy strategies
115. Antibody to a molecularly-defined antigen confined to a tumour cell surface
116. Detection of minimal residual cells carrying the t(14;18) by DNA sequence amplification
117. All advanced stage non-Hodgkin's lymphomas with a polymerase chain reaction amplifiable breakpoint of bcl-2 have residual cells containing the bcl-2 rearrangement at evaluation and after treatment
118. Induction of immune responses in patients with B-cell lymphoma against the surface-immunoglobulin idiotype expressed by their tumors
119. Tumor-specific idiotype vaccines in the treatment of patients with B-cell lymphoma-long-term results of a clinical trial
120. Complete molecular remissions induced by patient-specific vaccination plus granulocyte-monocyte colony-stimulating factor against lymphoma
121. The clinical significance of molecular response in indolent follicular lymphomas
122. A phase I/II trial to evaluate the immunogenicity of recombinant idiotype protein vaccines for the treatment of non-Hodgkin's lymphoma
123. Stimulation of cytotoxic T cells against idiotype immunoglobulin of malignant lymphoma with protein-pulsed or idiotype-transduced dendritic cells
124. Immune transfer studies in canine allogeneic marrow graft donor-recipient pairs
125. Immunologic chimerism as evidence of bone marrow graft acceptance in an identical twin with acute lymphocytic leukemia
126. The detection of specific antibody formation to recall antigens after human bone marrow transplantation
127. The transfer of antigen-specific humoral immunity from marrow donors to marrow recipients
128. Transfer of myeloma idiotype-specific immunity from an actively immunised marrow donor
129. Idiotype vaccination in human myeloma: Generation of tumor-specific immune responses after high-dose chemotherapy
130. Dendritic cell regulation of TH1-TH2 development
131. Issues on clinical applications of cancer vaccines